In this report, we investigated the mechanism responsible for synergistic induction of myeloma cell apoptosis induced by the combination of tipifarnib and bortezomib.
Introduction
We have previously reported that the farnesyl transferase inhibitor (FTI) lonafarnib (SCH66336) combined with the proteasome inhibitor bortezomib induced synergistic apoptosis in myeloma cell lines and primary patient cells, however, the mechanism responsible for this synergy was unclear.
1-5 While many groups have speculated that FTIs induce their effect via ras signalling, 6-8 others have suggested alternative pathways by which FTIs exert their anti-cancer effects. [9] [10] [11] Giannakakou and colleagues first reported that FTIs inhibit HDAC6 expression, resulting in destabilization of the microtubule assembly structure, and impaired cell survival in non-small cell lung cancer cell lines. 12 Based upon published preclinical data demonstrating that HDAC inhibitors synergize with proteasome inhibition via inhibition of aggresome formation, we sought to determine if the in vitro synergy we have
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Methods
The MM.1S (provided by S. Rosen, Chicago, IL), and RPMI8226 (ATCC, Manassas, VA) cell lines were used in this study. Tipifarnib (R115777) was provided by Johnson & Johnson Pharmaceuticals (Titusville, NJ) and bortezomib was provided by Millennium Pharmaceuticals (Cambridge, MA). MTT assays, Annexin V staining, and SDS-PAGE were performed according to previously published methods. 1, 5, 13 The antibodies utilized included anti-ubiquitin, anti-caspase-8, anti-caspase-9, anti-caspase-3, anti-poly-ADP ribose polymerase (Cell Signaling, Beverly, MA). p62SQSTM1 antibody (MBL International, Woburn, MA), bafilomycin A 1 and LC3B antibody (Sigma-Aldrich Inc., St. Louis, MO) were used to assess autophagy. Confocal microscopy was performed using standard methods with minor modifications in order to assess aggresome formation.
12, 13
Vimentin (SigmaAldrich Inc., St. Louis, MO) and gamma tubulin (abcam, Cambridge, MA) antibodies were used in the evaluation of aggresome formation by confocal immunoflourescence microscopy.
Results and Discussion
Consistent with our previous findings using lonafarnib in myeloma cells, the combination of tipifarnib and bortezomib resulted in greater growth inhibition than when either agent was used separately in both MM.1S as well as in RPMI8826 with concentrations up to 10nM of bortezomib and 5 µM of tipifarnib ( Figure 1 ). Combination therapy with low dose bortezomib and tipifarnib resulted in enhanced myeloma cell apoptosis which was demonstrated to be synergistic as evidenced by a low combination index (<0.6) in these MM cell lines (Supplemental Figure 1 ). We then determined the effects of single agent or combination therapy on ubiquitinated proteins in RPMI8226 cells using confocal fluorescence microscopy.
Consistent with previous findings, the use of bortezomib results in the accumulation of ubiquitinated protein aggregates in the cytoplasm (Figure 2A) , which was not seen with tipifarnib alone, and was enhanced when bortezomib and tipifarnib were given in combination. To further characterize the nature of these ubiquitin aggregates we investigated the other protein components of the aggregates. p62/SQSTM1 is a ubiquitin binding protein that is responsible for localizing ubiquitin-containing aggresomes with the autophagy membranes [14] [15] [16] [17] . As seen in figure 2A , p62SQSTM1 is colocalized with ubiquitin-containing aggregates suggesting that these aggregates are aggresomes. To validate these findings, we determined if other aggresome related proteins colocalized with the ubiquitin containing aggregates. Consistent with this possibility, vimentin also colocalized with the ubiquitin aggregate, while a tubulin was not part of the aggregate, however was proximal ( Figure 2B ), suggesting that the aggregates are proximal to the MTOC. Taken together, these data suggest that the aggregates that are accumulating are in fact aggresomes. The accumulation of aggresomes observed with combination therapy could result from inhibition of autophagy or the lysosome degradation of the aggresome late in the autophagy pathway.
To distinguish between these possibilities we investigated the effects of tipifarnib +/-bortezomib on the accumulation of LC3BII in the MM.1S and RPMI 8226 cell lines.
Activation of autophagy results in lipidation of LC3B which can be detected by faster migration of the protein in SDS-PAGE (LC3BII). As seen in Figure 2C , both p62SQSTM1
and LC3BII are increased when cells are treated with the combination of bortezomib and tipifarnib in MM.1S cells by western blotting. However since both LC3BII and p62 are 18 The accumulation of LC3BII was noted to occur independent of bortezomib or tipifarnib addition as well as the presence or absence of bafilomycin A 1 ( Figure 2C ). Since the increase in LCB3II occurred in the untreated and treated cells, these data suggest that autophagy is active in these cells and unaffected by exposure to bortezomib, tipifarnib or the combination. However, among cells treated with bafilomycin A 1 , p62SQSTM1 expression was increased only in the untreated cells. In aggregate these data suggest that tipifarnib blocks lysosomal-dependant degradation of bortezomib induced aggresomes without inhibition of the early steps of autophagy.
The aggresome/autophagy pathway is an important accessory pathway that is critical for the degradation of many proteins, and is even more important when the proteasome/ubiquitin pathway is blocked. The combination of LBH589, vorinostat, or romidepsin with bortezomib has been shown to inhibit aggresome formation and result in apoptosis likely as a result of accumulation of toxic proteins that are not subsequently packaged for disposal via the aggresome/autophagy pathway. 13, [19] [20] [21] [22] [23] [24] [25] It has been presumed that accumulation of unpackaged misfolded proteins is toxic to cells, and that packaging of these proteins into aggresomes results in their disposal and therefore protects the cell from toxic injury. However, the pathway for catabolism of proteins via autophagy may be more complex. Aggresome formation and packaging of proteins for degradation is clearly an
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From important step in the cells ability to manage misfolded proteins; however it must be coupled with efficient delivery of the aggresome to the autophagosome for degradation. Our current data supports the hypothesis that in addition to aggresome formation, aggresome disposal is an equally important step in the process, one that can be regulated by agents such as tipifarnib, and therefore represents a novel drug target. In addition, the packaging of misfolded proteins alone is not sufficient to protect the cell as accumulation of aggresomes without appropriate disposal can also induce apoptosis as demonstrated by our data.
Accumulation of aggresomes represents a novel mechanism by which to induce apoptosis, especially among cells where protein production and catabolism are critically important for malignant cell survival as is the case for malignant and normal immunoglobulin producing plasma cells. We have demonstrated that when tipifarnib is combined with bortezomib in malignant plasma cells, aggresome formation is enhanced, yet there is an uncoupling of aggresome formation from autophagic degradation that leads to synergistic apoptosis.
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